XARELTO® is the #1 prescribed novel oral anticoagulant in the US*1
IMPORTANT CORRECTION OF DRUG INFORMATION
Incorrect dosing information was inadvertently displayed on this website recently. This has been corrected as of March 19, 2014. Please see the full Prescribing Information and Medication Guide, which were not affected. Click here for correct Dosing Information. Click here for Healthcare Professional Letter.
XARELTO® is available for multiple indications:
Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
The prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.
*Among Factor Xa inhibitors and direct thrombin inhibitors.
Data on file. Janssen Pharmaceuticals, Inc. Based on IMS Health, NPA Weekly, May 2014.